This website uses cookies We use cookies that are necessary for the operation of the website. You consent to these "Necessary" cookies if you continue to use our website. We also use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners, who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You can decide which of these other categories of "Preferences," "Statistics" and "Marketing" cookies you would like to permit. To learn more about your choices, please mouse over each checkbox or click on "Show details." I ACCEPT Necessary Preferences Statistics Marketing Show details Opening a new era of medicine Learn more about our programs News Update NOVEMBER 22, 2021 Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) Overview Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. Learn About Our Mission Programs & Pipeline Each one of us together for patients We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases. Join Us. See how you can change life stories with genome editing Learn More Full-Spectrum Blog Opening a New Era of Medicine Read the full article Follow Us on Social Media NOVEMBER 22, 2021 $NTLA News: @MHRAgovuk approves protocol amendment to include patients with #ATTR amyloidosis with cardiomyopathy in Intellia’s ongoing Phase 1 study of NTLA-2001. More details here: https://t.co/7sO49vzNj2 #CRISPR #genomeediting https://t.co/28ii2rGGAA View on Twitter NOVEMBER 17, 2021 Tomorrow, Intellia VP, Disease Biology, Sean Burns, M.D., will be speaking at the #CRISPR 2.0 Summit hosted by @HansonWade on the development of systemic CRISPR-based therapeutics. Learn more: https://t.co/KrvNBUtsR9 #genomeediting https://t.co/lQEAl30prx View on Twitter You can also follow us on: Info Overview Leadership Partners Healthcare Professionals Overview CRISPR/Cas9 What’s CRISPR/Cas9? How CRISPR/Cas9 Works Types of Edits Glossary Investors & Media Overview Press Releases Corporate Deck Events & Presentations Press Kit Corporate Governance Financial Info Stock Info Analyst Coverage Investor Resources Programs & Pipeline Intellia’s Full-Spectrum Approach Pipeline In Vivo Therapies Ex Vivo Therapies Careers Life @ Intellia Join Us Patients & Families Our Commitment Clinical Trials Community Perspectives & Resources Expanded Access Policy © Intellia Therapeutics, Inc. 2021 Cookie Policy Terms of Use Privacy Policy Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.